Business Wire

SEOUL-SEMICONDUCTOR

Share
Seoul Semiconductor: The #1 in Patent Power Pre-empting the Future with 2nd Generation LED Technologies

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a global optical semiconductor company, announced that Seoul Semiconductor and Seoul Viosys (hereafter referred to as Seoul ) are Korea's #1 optical semiconductor (LED) companies and are among the world's #1 patent-powered companies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005986/en/

Seoul is ranked first in the world in the ultraviolet (UV) LED field, developing and mass-producing these LEDs. It is ranked third in the visible-light LED category for the past two years. Its visible-light LEDs are widely used in lighting, displays, and automobiles. Seoul is on the path to being ranked #1.

Seoul is the only company in the world to offer the entire wavelength range from visible light to ultraviolet and infrared, in light-emitting diodes as well as laser diodes (VCSEL). In addition, Seoul is 100% vertically integrated with production capacity for all of these technologies: from wafers and chips to packages and modules.

Seoul is investing nearly $100 million in R&D every year and pouring out innovative LED technologies at a staggering rate. Its collection of patents is unrivaled in the LED industry.

Regarding technology patents, there are thousands of patents for applications related to other major industries. Almost none of the LED products in the world today can be produced unless Seoul approves the use of its patents.

Ready to leap to be #1 in the world with innovative 2nd generation technologies

LEDs recently sold on the market require a patent of Seoul for that enables 10,000+ hours of lifetime, the efficiency of 150 lm/W, and high-quality color quality (CRI 90+). Since Seoul’s founder CH Lee started the company 30 years ago, he has worked tirelessly alongside his teams (and still is today) to develop a collection of patents that protects these new technologies and his company’s future. Although we are not all created equal, CH Lee wants to show that there is hope and fair opportunity in the patent system for young people.

Lighting: good sleep, good memory, good eye health

Since the birth of the earth 4.5 billion years ago, the string of life has evolved under the influence of Sun’s light. As a result, our human body operates on a 24-hour basis following the cycle of the sun. In the morning sunlight, the body releases the serotonin hormone to raise awareness. It releases the melatonin hormone under the influence of early evening sunlight to help us sleep. A good night's sleep removes waste from the brain, strengthens memory, and helps our body recover.

Many LED lighting products today produce a significant amount of blue light. This light makes it harder to fall asleep and sleep more deeply. In addition, exposure to excessive blue light can lead to myopia in children.

Seoul has conducted experiments with various institutions across the globe to prove the amazing benefits of SunLike. These studies confirmed that SunLike lighting prevents myopia, and improves sleep and working memory. This research was conducted by the Center for Clinical Investigation (CCI) at Brigham and Women's Hospital at Harvard University in the U.S, University of Basel in Switzerland, Seoul National University in Korea, and SERI Ophthalmology Institute in Singapore. For more information, visit Seoul Semiconductor's website (http://www.seoulsemicon.com/en/technology/sunlike/ ).

Automotive: WICOP LED Technology is required for communication by autonomous vehicles

For the safety of drivers and pedestrians, Vehicle to Everything (V2X) lighting technology recognizes and communicates with surrounding objects and is essential for self-driving cars. To realize V2X lighting technology, a new concept of WICOP technology with a robust structure without wires is essential. WICOP is already being adopted by nearly 10 percent in the headlights of top-brand cars in Europe, the U.S, and Korea, and is becoming the standard for all LEDs.

Displays: Ultra-high-definition micro and mini LED from TV to Tablet

Mini LEDs are used to increase the quality of LCDs, and WICOP LEDs that do not require existing wires are essential to use micro LEDs for wearable devices such as future watches and AR/VRs. WICOP was introduced to the world in 2015 by CH Lee to the global press at the Intercontinental Hotel in Shanghai, China. Today, this technology is adopted in nearly 20% of all displays. Seoul is the world's #1 player in Display.

Besides vaccines and other medical treatments, we need to find ways to prevent the virus from spreading. As newly mutated viruses continue to emerge, it is time for a fundamental solution to prevent the virus from entering the human body other than vaccines or treatments.

Some of Seoul’s most recent studies have shown that Violeds technology kills 99% of Delta and Omicron variants in just one second. During the same experiment, a reduction in the number of viruses in the air was confirmed for more than 90% within 20-30 minutes, which can lead to significantly lower infection rates. For more information about this and other studies, please visit the Seoul Viosys’ website(http://www.seoulviosys.com/en/applications/sterilization ).

CH Lee’s commitment and philosophy to technology development

CH Lee believes that in developed countries where patents are respected, industries develop more and people live better lives. The 18th -century industrial revolution lowered the poverty rate from 85% to 3% or less, and the infant mortality rate from 43% to 3%. The spread of the availability of electricity and the Internet decreased the illiteracy rate. Thus, information became universally accessible and eventually improved human rights. More importantly, the patent system brings 'fair opportunity' and creates a society with a little more hope.

It angers CEO Lee that there are still two-faced patent infringers prevalent who emphasize environmental, social, and corporate governance while selling obviously infringed products by changing labels or who are willing to buy infringing products for a cheap price. By defending his IP vigorously, he wants to give young people hope that fairness does exist. He will not cut his hair to show his fighting spirit and at the least encourage young people to keep their fighting spirit up as well.

About Seoul Semiconductor

Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all-direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en .

Link:

ClickThru

Social Media:

https://www.facebook.com/seoulsemiconductorglobal

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release

- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least

Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release

-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release

Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou

Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi

Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release

Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye